Literature DB >> 29127023

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Andrew G Nicholson1, Kathleen Torkko2, Patrizia Viola3, Edwina Duhig4, Kim Geisinger5, Alain C Borczuk6, Kenzo Hiroshima7, Ming S Tsao8, Arne Warth9, Sylvie Lantuejoul10, Prudence A Russell11, Erik Thunnissen12, Alberto Marchevsky13, Mari Mino-Kenudson14, Mary Beth Beasley15, Johan Botling16, Sanja Dacic17, Yasushi Yatabe18, Masayuki Noguchi19, William D Travis20, Keith Kerr21, Fred R Hirsch2, Lucian R Chirieac22, Ignacio I Wistuba23, Andre Moreira24, Jin-Haeng Chung25, Teh Ying Chou26, Lukas Bubendorf27, Gang Chen28, Giuseppe Pelosi29, Claudia Poleri30, Frank C Detterbeck31, Wilbur A Franklin2.   

Abstract

Multiple tumor nodules are seen with increasing frequency in clinical practice. On the basis of the 2015 WHO classification of lung tumors, we assessed the reproducibility of the comprehensive histologic assessment to distinguish second primary lung cancers (SPLCs) from intrapulmonary metastases (IPMs), looking for the most distinctive histologic features. An international panel of lung pathologists reviewed a scanned sequential cohort of 126 tumors from 48 patients and recorded an agreed set of histologic features, including tumor typing and predominant pattern of adenocarcinoma, thereby opining whether the case was SPLC, IPM, or a combination thereof. Cohen κ statistics of 0.60 on overall assessment of SPLC or IPM indicated a good agreement. Likewise, there was good agreement (κ score 0.64, p < 0.0001) between WHO histologic pattern in individual cases and SPLC or IPM status, but the proportions diversified for histologic pattern and SPLC or IPM status (McNemar test, p < 0.0001). The strongest associations for distinguishing between SPLC and IPM were observed for nuclear pleomorphism, cell size, acinus formation, nucleolar size, mitotic rate, nuclear inclusions, intraalveolar clusters, and necrosis. Conversely, the associations for lymphocytosis, mucin content, lepidic growth, vascular invasion, macrophage response, clear cell change, acute inflammation keratinization, and emperipolesis did not reach significance with tumor extent. Comprehensive histologic assessment is recommended for distinguishing SPLC from IPM with good reproducibility among lung pathologists. In addition to main histologic type and predominant patterns of histologic subtypes, nuclear pleomorphism, cell size, acinus formation, nucleolar size, and mitotic rate strongly correlate with pathologic staging status.
Copyright © 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Interobserver variation; Lung cancer; Multiple tumors; Pathology

Mesh:

Year:  2017        PMID: 29127023      PMCID: PMC6276791          DOI: 10.1016/j.jtho.2017.10.019

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  18 in total

1.  Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.

Authors:  William D Travis; Elisabeth Brambilla; Allen P Burke; Alexander Marx; Andrew G Nicholson
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

Review 2.  The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Authors:  William D Travis; Hisao Asamura; Alexander A Bankier; Mary Beth Beasley; Frank Detterbeck; Douglas B Flieder; Jin Mo Goo; Heber MacMahon; David Naidich; Andrew G Nicholson; Charles A Powell; Mathias Prokop; Ramón Rami-Porta; Valerie Rusch; Paul van Schil; Yasushi Yatabe
Journal:  J Thorac Oncol       Date:  2016-04-21       Impact factor: 15.609

3.  The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Andrew G Nicholson; Kari Chansky; John Crowley; Ricardo Beyruti; Kaoru Kubota; Andrew Turrisi; Wilfried E E Eberhardt; Jan van Meerbeeck; Ramón Rami-Porta
Journal:  J Thorac Oncol       Date:  2015-12-24       Impact factor: 15.609

4.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Ramón Rami-Porta; Vanessa Bolejack; John Crowley; David Ball; Jhingook Kim; Gustavo Lyons; Thomas Rice; Kenji Suzuki; Charles F Thomas; William D Travis; Yi-Long Wu
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

6.  Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.

Authors:  Nicolas Girard; Charuhas Deshpande; Christopher Lau; David Finley; Valerie Rusch; William Pao; William D Travis
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

7.  Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis.

Authors:  Xin Luo; Xiao Zang; Lin Yang; Junzhou Huang; Faming Liang; Jaime Rodriguez-Canales; Ignacio I Wistuba; Adi Gazdar; Yang Xie; Guanghua Xiao
Journal:  J Thorac Oncol       Date:  2016-11-04       Impact factor: 15.609

8.  Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.

Authors:  Nicolas Girard; Charuhas Deshpande; Christopher G Azzoli; Valerie W Rusch; William D Travis; Marc Ladanyi; William Pao
Journal:  Chest       Date:  2009-04-17       Impact factor: 9.410

9.  The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Frank C Detterbeck; Wilbur A Franklin; Andrew G Nicholson; Nicolas Girard; Douglas A Arenberg; William D Travis; Peter J Mazzone; Edith M Marom; Jessica S Donington; Lynn T Tanoue; Valerie W Rusch; Hisao Asamura; Ramón Rami-Porta
Journal:  J Thorac Oncol       Date:  2016-03-02       Impact factor: 15.609

10.  Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features.

Authors:  Kun-Hsing Yu; Ce Zhang; Gerald J Berry; Russ B Altman; Christopher Ré; Daniel L Rubin; Michael Snyder
Journal:  Nat Commun       Date:  2016-08-16       Impact factor: 14.919

View more
  10 in total

1.  Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases.

Authors:  Laura Bonanno; Alberto Pavan; Stefano Indraccolo
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Prognostic Impact of Tumor Doubling Time in Patients with Metachronous Lung Cancer.

Authors:  Keisuke Asakura; Yukihiro Yoshida; Hiroyuki Sakurai; Kazuo Nakagawa; Noriko Motoi; Shun-Ichi Watanabe
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

3.  Clonality analysis of pulmonary tumors by genome-wide copy number profiling.

Authors:  Julien P L Vincenten; Hendrik F van Essen; Birgit I Lissenberg-Witte; Nicole W J Bulkmans; Oscar Krijgsman; Daoud Sie; Paul P Eijk; Egbert F Smit; Bauke Ylstra; Erik Thunnissen
Journal:  PLoS One       Date:  2019-10-16       Impact factor: 3.240

4.  Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.

Authors:  Donglin Zhu; Dan Cao; Minghong Shen; Jinghuan Lv
Journal:  BMC Cancer       Date:  2021-02-18       Impact factor: 4.430

5.  Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors.

Authors:  Yasuhiro Koh; Tomoya Kawaguchi; Motohiro Izumi; Jun Oyanagi; Kenji Sawa; Mitsuru Fukui; Koichi Ogawa; Yoshiya Matsumoto; Yoko Tani; Tomohiro Suzumura; Tetsuya Watanabe; Hiroyasu Kaneda; Shigeki Mitsuoka; Kazuhisa Asai; Masahiko Ohsawa; Nobuyuki Yamamoto
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

Review 6.  Recent Advances in the Diagnosis and Management of Multiple Primary Lung Cancer.

Authors:  Chi-Lu Chiang; Ping-Chung Tsai; Yi-Chen Yeh; Yuan-Hung Wu; Han-Shui Hsu; Yuh-Min Chen
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

7.  Artificial neural network in the discrimination of lung cancer based on infrared spectroscopy.

Authors:  Eiron John Lugtu; Denise Bernadette Ramos; Alliah Jen Agpalza; Erika Antoinette Cabral; Rian Paolo Carandang; Jennica Elia Dee; Angelica Martinez; Julius Eleazar Jose; Abegail Santillan; Ruth Bangaoil; Pia Marie Albano; Rock Christian Tomas
Journal:  PLoS One       Date:  2022-05-12       Impact factor: 3.752

8.  Reproducibility and Feasibility of Classification and National Guidelines for Histological Diagnosis of Canine Mammary Gland Tumours: A Multi-Institutional Ring Study.

Authors:  Serenella Papparella; Maria Ines Crescio; Valeria Baldassarre; Barbara Brunetti; Giovanni P Burrai; Cristiano Cocumelli; Valeria Grieco; Selina Iussich; Lorella Maniscalco; Francesca Mariotti; Francesca Millanta; Orlando Paciello; Roberta Rasotto; Mariarita Romanucci; Alessandra Sfacteria; Valentina Zappulli
Journal:  Vet Sci       Date:  2022-07-13

9.  Metachronous primary lung adenocarcinomas harboring distinct KRAS mutations.

Authors:  Yan Hu; Siying Ren; Chen Chen; Qingchun Liang; Fenglei Yu; Wenliang Liu
Journal:  Thorac Cancer       Date:  2020-05-16       Impact factor: 3.500

10.  Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.

Authors:  Alfredo Addeo; Giuseppe Luigi Banna; Giulio Metro; Massimo Di Maio
Journal:  Front Oncol       Date:  2019-04-16       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.